Across the innovation and development, new layout of the biomedical industry
Author: Shenzhen ZhongJian South Environment CO., LTDissuing time:2017-02-21 18:28:48Pageviews:4553【smallinBig】
July 8, the Beijing Municipal Government Information Office and the Beijing Municipal Science and Technology Commission jointly organized the \"Beijing Technology Innovation Action Plan (2014-2017)\" of the biomedical industry across the development of special series of results conference. Beijing Municipal Science and...
Text label：
July 8, the
Beijing Municipal Government Information Office and the Beijing
Municipal Science and Technology Commission jointly organized the
"Beijing Technology Innovation Action Plan (2014-2017)" of the
biomedical industry across the development of special series of results
conference. Beijing Municipal Science and
Technology Commission, deputy director of Zheng Huanmin introduction,
the capital of the biomedical industry through the special
implementation, formed a new pattern of innovation across the
development.
Strengthen the layout of major projects
In
2014, the Beijing Municipal Government issued the implementation of the
"Beijing Technology Innovation Action Plan", and actively speed up the
construction of enterprises as the mainstay of technological innovation
system, and continuously improve the ability of independent innovation,
accelerate the industrialization of scientific and technological
achievements and new technologies to promote the use of new products to
promote Urban sustainable development and services to the people's livelihood
needs to provide scientific and technological support, the formation of
innovation-driven development pattern.
"Biomedical
industry leapfrog development" special action plan is identified as one
of the 12 major projects, the municipal government to implement the
"healthy China" "Health Beijing" in science and technology support an
important measure. The
special task of the deployment of two key tasks: "to achieve pillar
industry by leaps and bounds" and "improve the innovation-driven policy
system." By 2017, the biomedical industry and strive to become a pillar industry.
At
present, the Beijing biomedical industry has formed a life science and
health medicine cutting-edge technology, biomedical industry, clinical
medicine research trinity overall technology layout. To
the clinical needs of traction, cutting-edge technology to support,
build and improve the Beijing biomedical industry innovation system. The G20 project has been implemented since 2010. In
accordance with the twenty-eight rule, "G20" implication is the focus
and service industry key leading enterprise development, and play their
leading role in promoting the Beijing biomedical industry across the
comprehensive development. It is reported that, G20 project after two, has formed a series of results.
Biomedicine into the capital billion industry
According
to reports, "Eleventh Five-Year" at the end of the Beijing
pharmaceutical industry's main business income of less than 40 billion
yuan, "second five" at the end of about 130 billion yuan, an average
annual growth rate of 16%, Beijing's new 100 billion industry The The
total profits of the pharmaceutical industry to maintain the top five,
the sales profit rate has always been the first in the country, the
pharmaceutical industry added value rose to the city's second place. 57
G20 enterprises in more than one billion yuan scale enterprises from 7
in 2010 to 2015 growth of 13, the birth of the first 10 billion
enterprises Bayer medicine. 57
G20 enterprises played a central role, as of December 2015 to achieve
operating income of 56.65 billion yuan, accounting for 58.1% of the
city's pharmaceutical industry. In the economic development into a new normal macroeconomic situation,
the growth rate of bio-pharmaceutical industry from high-speed growth
gradually to high-speed growth.
"Four-wheel drive" development pattern continues to consolidate. The
biomedical industry has formed a development pattern dominated by
chemical medicine, traditional Chinese medicine, bio-pharmaceuticals and
medical devices, and achieved operating income and profit of 93% of the
pharmaceutical manufacturing industry. Among them, the chemical pharmaceutical has a prominent brand
advantage and high scale advantages, bio-pharmaceutical manufacturing
industry growth is strong.
The development of the capital of the biomedical industry, the quality and efficiency of continuous improvement. Strategic
layout cutting-edge technology to improve the ability to innovate in
stem cells and tissue engineering, structural biology, biological 3D
printing and other fields has made breakthrough progress. Industrial
innovation capacity continues to improve, the emergence of a number of
heavy varieties, innovative products and key enterprises. And bio-pharmaceutical research and development related to the
surrounding clean room purification project also brings a great
opportunity for development.
According
to reports, "Twelfth Five-Year Plan" period, Beijing made new clinical
documents more than 300, the number of the first in the country; access
to more than 370 drug approval number, Beijing pharmaceutical
manufacturing sales rate for 10 consecutive years in the country's major
pharmaceutical developed provinces and cities In the first place. Beijing
Yi Qiao Shenzhou Biotechnology Co., Ltd. Technical Director Zhang Jie
introduction, Yi Qiao China has more than 70 countries and regions, more
than 8,000 units to provide quality and cheap protein, antibody
reagents, to achieve the field of biomedical "Made in China "Brand to enter the international market breakthrough.
"One South One North" spatial pattern is initially formed. It
is reported that Beijing has initially formed a "one South and one
North, each with its own characteristics" of the biomedical industry
space layout, "South" includes Yizhuang and Daxing biological medicine
base as the core of high-end industrial base, "North" including
Zhongguancun Life Science Park As the core R & D Innovation Center.
Aimed at the industry "pain point" continuous research
In addition, the Beijing Municipal Science and Technology Commission
to actively play the role of the main market, around the impact of
enterprise development funds, space, technology, policy, R & D
services five key "pain point" to carry out the relevant work.
Biomedical industry has a long research and development cycle, capital investment, high risk characteristics. In
order to solve the problem of small and medium-sized enterprises in
biomedical enterprises, the Municipal Science and Technology Commission
and the financial management departments, commercial banks and guarantee
institutions to implement the "biomedical industry financial incentive
pilot program" to take the loan risk compensation, loan risk
compensation, Twelve Five "period, to guide the 20 commercial financial institutions
accumulated for 247 enterprises to issue loans of nearly 20 billion
yuan, reflecting the technology" signal source ", financial" amplifier
"role.
To
promote the enterprise to become the main body of technological
innovation decision-making, science and technology investment,
scientific research organization and achievement transformation, and to
improve the technological innovation of biomedical enterprises to
promote the enterprises to become the key elements of technological
innovation decision-making, science and technology investment,
scientific research organization and achievement transformation Ability and core competencies.
Beijing is also actively play the leading role of talent supply technology innovation. High-end
talent team is the fundamental enterprise innovation, in order to
achieve high-end talent gathering, to carry out "G20 engineering talent
action", "outside cited" overseas leader, "inline" local high-end
talent, "nurturing" applied talents. As of the "second five" at the end, Beijing has 42 biomedical
entrepreneurs selected "thousands of people plan", 101 biomedical
experts selected "sea poly project."
Multi-commission office linkage, and promote the use of innovative varieties listed. Beijing
Municipal Science and Technology Commission in conjunction with the
city by the letter, Zhongguancun Management Committee, City Investment
Promotion Bureau, City Food and Drug Administration, Municipal Health
Commission and other departments to form a linkage mechanism in the
health insurance directory, drug pricing, tender procurement and
registration approval , To accelerate the biomedical innovation varieties listed. To
G20 major innovative varieties of enterprises as the representative of
the 88 varieties of drugs into the Beijing Medicare directory, the
Beijing Municipal Science and Technology Commission jointly issued by
the City Planning Commission to promote the tender market to make the
local market share of drugs from 8% to 13%, the joint city of food and
medicine Bureau to promote the first batch of five new drugs into the "Beijing
biomedical innovation to promote the platform" green channel to speed up
the progress of drug approval.
Play the support of technical service to industrial development. With
ABO as the starting point to promote the development of R & D
technical service industry, ABO alliance formed 6 proprietary technology
platforms such as "chemical synthesis and preparation", "protein
antibody" and "preclinical evaluation". Service innovation more than 2,000 varieties, to promote the
development of the capital biomedical research and development service
industry main force.
"13th
Five-Year Plan" period, the Beijing Municipal Science and Technology
Commission will continue to "bio-pharmaceutical industry across the
development of" special as the carrier, in Beijing to build the National
Science and Technology Innovation Center and Beijing-Tianjin-Hebei
cooperation in the development of new situations, combined with domestic
and international biomedical industry trends And
improve the technical service platform to support innovation and
entrepreneurship; to strengthen the Beijing-Tianjin-Hebei industrial
cooperation, to promote coordinated development; to promote the policy
first try again and again, to promote innovation and cultivate efforts
to accelerate the high-end output; , Strengthen the system innovation and other five aspects of the focus
of work, focus and layout of the industrial transformation and
upgrading and sophisticated development.
The
development of biopharmaceuticals will certainly lead the development
of related industries, such as pharmaceutical clean room engineering,
biological laboratory purification projects, and bio-pharmaceutical
development will also usher in the development of spring. Shenzhen
City in the construction of the Southern Environmental Limited limited
work as a bio-pharmaceutical clean room engineering industry leading
brand, over the years by virtue of their own experience and strength,
has been committed to creating high-end clean room purification project,
serving the development of bio-pharmaceutical industry is expected in
the future, The biopharmaceutical industry will bring a leap across innovation.
2017-02-21
4553People browsing
Back
